Aspen Aerogels (NYSE:ASPN) Price Target Increased to $28.00 by Analysts at Canaccord Genuity Group

Aspen Aerogels (NYSE:ASPN) had its price target upped by Canaccord Genuity Group from $18.00 to $28.00 in a research note released on Friday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the construction company’s stock.

Other research analysts also recently issued reports about the company. Piper Sandler raised their price objective on Aspen Aerogels from $20.00 to $29.00 and gave the company an overweight rating in a research note on Friday. HC Wainwright raised their price objective on Aspen Aerogels from $20.00 to $25.00 and gave the company a buy rating in a research note on Friday. TheStreet raised Aspen Aerogels from a d+ rating to a c- rating in a research note on Wednesday, March 6th. B. Riley raised their price objective on Aspen Aerogels from $24.00 to $30.00 and gave the company a buy rating in a research note on Friday. Finally, Roth Mkm reissued a buy rating and issued a $22.00 price objective on shares of Aspen Aerogels in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $25.17.

Aspen Aerogels Stock Up 5.3 %

ASPN opened at $25.11 on Friday. Aspen Aerogels has a fifty-two week low of $5.32 and a fifty-two week high of $25.65. The business has a 50-day moving average of $16.72 and a 200-day moving average of $13.77. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.41 and a quick ratio of 2.91. The company has a market capitalization of $1.93 billion, a PE ratio of -57.07 and a beta of 1.97.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings results on Tuesday, February 13th. The construction company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.11. Aspen Aerogels had a negative return on equity of 6.54% and a negative net margin of 10.73%. The company had revenue of $84.22 million during the quarter, compared to the consensus estimate of $83.82 million. During the same period last year, the business earned ($0.20) EPS. Equities research analysts forecast that Aspen Aerogels will post 0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Aspen Aerogels

Large investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise grew its holdings in shares of Aspen Aerogels by 37.5% during the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock worth $81,000 after purchasing an additional 1,252 shares during the last quarter. McAdam LLC bought a new stake in shares of Aspen Aerogels during the fourth quarter valued at approximately $191,000. Mirae Asset Global Investments Co. Ltd. raised its position in Aspen Aerogels by 71.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,052 shares of the construction company’s stock worth $198,000 after purchasing an additional 9,601 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Aspen Aerogels by 38.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,971 shares of the construction company’s stock valued at $205,000 after buying an additional 3,607 shares during the last quarter. Finally, Cornerstone Investment Partners LLC bought a new position in Aspen Aerogels in the fourth quarter valued at about $230,000. 97.64% of the stock is currently owned by institutional investors.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.